Position in MRK
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$986,109
+$213,607 QoQ
Shares Held
7,674
+19.5% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#2,130
of 3,769 holders
Holding Since
Jun 2023
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MRK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026F/m Investments LLC holds $52,996,280 across 11 Drug Manufacturers - General names. MRK ranks #7 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
24,561 | $29,459,202 | |
| 2 | JNJ |
Johnson & Johnson
|
39,177 | $9,949,782 | |
| 3 | ABBV |
AbbVie Inc.
|
24,521 | $6,170,464 | |
| 4 | AMGN |
Amgen Inc
|
4,809 | $1,741,435 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
24,103 | $1,388,814 | |
| 6 | PFE |
Pfizer Inc
|
47,630 | $1,146,930 | |
| 7 | MRK |
Merck & Co., Inc.
This page
|
7,674 | $986,109 | |
| 8 | GSK |
GSK plc
|
15,772 | $826,768 |
All Filings in MRK
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $986,109 | 7,674 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $772,502 | 6,422 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $3,755,150 | 35,675 | Shares | Sole | 2026-02-03 | |
| 2025-09-30 | $2,852,780 | 33,990 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $2,156,714 | 27,245 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $2,582,125 | 28,767 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $2,805,435 | 28,201 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $3,070,662 | 27,040 | Shares | Sole | 2024-10-29 | |
| 2024-06-30 | $4,001,958 | 32,326 | Shares | Sole | 2024-07-29 | |
| 2024-03-31 | $255,455 | 1,936 | Shares | Sole | 2024-04-23 | |
| 2023-06-30 | $210,009 | 1,820 | Shares | Sole | 2023-07-31 | |
| No filing history on record for this holder in this stock. | ||||||